$73.00
-1.74-2.33%
Last update: Nov 10, 12:11 PM
CG Oncology Inc
CGONNASDAQ
CG Oncology rose 85.8% from $40.22 to $74.74, ahead of the S&P 500's +10.5%. Its worst day was Oct 6 (−7.4%), and its low came Dec 17 at $37.37.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.57 missed the $-0.56 estimate on $1.7M revenue (est. $175,536.00).
+8.6% · S&P 500 0.0%
CG Oncology closed at its lowest level of the year, 7.1% below where the year started.
Story events cover the past 12 months · Times ET
−1.3% · S&P 500 −1.1%
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule- First randomized registrational trial to evaluate an
+29.3%, the year's best day, on 7M shares, the year's heaviest volume · S&P 500 +0.7%
EPS of $-0.51 beat the $-0.59 estimate on $2.3M revenue (est. $1.6M).
+4.8% · S&P 500 −0.5%
CG Oncology shares rose 10.7%, while the S&P 500 rose 1.2%.
+10.7% · S&P 500 +1.2%
EPS of $-0.71 missed the $-0.55 estimate on $1.1M revenue (est. $512,632.00).
+0.6% · S&P 500 +0.8%
EPS of $-0.90 missed the $-0.65 estimate on $1.2M revenue (est. $831,792.00).
+3.4% · S&P 500 −0.2%
CG Oncology closed at its highest level of the year, 100.6% above where the year started.
+5.8% · S&P 500 +0.2%
EPS of $-0.64 beat the $-0.82 estimate on $1.6M revenue (est. $643,584.00).
+17.3% · S&P 500 +0.3%
Where it ended: a close of $74.74 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 26, 2027 (EPS est. $-0.72, revenue est. $1.8M).
Nothing in the past 12 months.
All CGON dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CGON and SPY from Benzinga historical bars. Not investment advice.
